The Role of Cell Cycle Proteins in Glomerular Disease

Seminars in Nephrology

Volumn 23, Issue 6, 2003, Pages 569-582

  Griffin, Siân V ^a   Pichler, Raimund ^a   Wada, Takehiko ^a   Vaughan, Michael ^a   Durvasula, Raghu ^a   Shankland, Stuart J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN;

APOPTOSIS; CELL CYCLE; CELL DAMAGE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; ENDOTHELIUM CELL; GLOMERULOPATHY; GLOMERULUS; HUMAN; MESANGIUM CELL; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 0346335995     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/S0270-9295(03)00133-5     Document Type: Article

References (134)

1. Nurse P: A long twentieth century of the cell cycle and beyond. Cell 100:71-78, 2000
2. Harper JW, Adams PD: Cyclin dependent kinases. Chem Rev 101:2511-2526, 2001
3. Evans T, Rosenthal TE, Youngblom J, et al: Cyclin: A protein specified by maternal mRNA in seas urchin eggs that is destroyed at each cleavage division. Cell 33:389-396, 1983
4. Koepp DM, Harper JW, Elledge SJ: How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 97:431-434, 1999
5. Pines J: Cyclins and cyclin dependent kinases: A biochemical view. Biochem J 308:697-711, 1995
6. Winston JT, Coats SR, Wang Y-Z, et al: Regulation of the cell cycle machinery by oncogenic Ras. Oncogene 12:127-134, 1996
7. Filmus J, Robles AI, Shi W, et al: Induction of cyclin D1 overexpression by activated ras. Oncogene 9:3627-3633, 1994
8. Aktas H, Cai H, Cooper GM: Ras links growth factor signalling to the cell cycle machinery via regulation of cyclin D1 and the cdk-inhibitor p27kip1. Mol Cell Biol 17:3850-3857, 1997
9. Gille H, Downward J: Multiple Ras effector pathways contribute to G1 cell cycle progression. J Biol Chem 274:22033-22040, 1999
10. Peeper DS, Upton TM, Ladha MH, et al: Ras signalling linked to the cell cycle machinery by the retinoblastoma protein. Nature 386:177-181, 1997
11. Cheng M, Sexl V, Sherr CJ, et al: Assembly of cyclin D dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A 95:1091-1096, 1998
12. Diehl JA, Cheng M, Roussel M, et al: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localisation. Genes Dev 12:3499-3511, 1998
13. Sherr CJ: Mammalian G1 cyclins. Cell 73:1059-1065, 1993
14. Kaldis P: The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol Life Sci 55:284-296, 1999
15. Matsushime H, Quelle DE, Shurtleff SA, et al: D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 19:191-198, 1994
16. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995
17. Kitagawa M, Higashi H, Jung HK, et al: The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 15:7060-7069, 1996
18. Lundberg AS, Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-CDK complexes. Mol Biol Cell 18:753-761, 1998
19. Smits VAJ, Medema RH: Checking out the G2/M transition. Biochim Biophys Acta 1519:1-12, 2001
20. Atherton-Fessler S, Parker LL GR, Piwnica-Worms H: Mechanisms of p34cdc2 regulation. Mol Cell Biol 13:1675-1685, 1993
21. Krek W, Nigg EA: Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: Identification of major phosphorylation sites. EMBO J 10:305-316, 1991
22. Parker LL, Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257:1955-1957, 1992
23. Li J, Meyer AN, Donoghue DJ: Requirement for phosphorylation of cyclin B1 for Xenopus oocyte maturation. Mol Cell Biol 6:1111-1124, 1995
24. Nilsson I, Hoffmann I: Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4:107-114, 2000
25. Yang J, Bardes ESG, Moore JD, et al: Control of cyclin B1 localisation through regulated binding of the nuclear export factor CRM1. Genes Dev 12:2131-2143, 2002
26. Hagting A, Jackman M, Simpson K, et al: Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr Biol 9:680-689, 1999
27. Sherr CJ, Roberts JM: CDK inhibitors: Positive and negative regulators of G1 phase progression. Genes Dev 13:1501-1512, 1999
28. Nakayama K-I, Nakayama K: Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays 20:1020-1029, 1998
29. Smits VAJ, Klompmaker R, Vallenius T, et al: p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem 275:30638-30643, 2000
30. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501, 1998
31. Cheng M, Olivier P, Diehl JA, et al: The p21cip1 and p27kip1 cdk "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18:1571-1583, 1999
32. El-Deiry WS, Tokino Y, Velculescu VE, et al: WAF1, a potential mediator of p53 tumour suppression. Cell 75:817-825, 1993
33. Xiong Y, Hannon GJ, Zhang H, et al: p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
34. Harper JW, Adami GR, Wei N, et al: The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
35. LaBaer J, Garrett M, Stevenson L, et al: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862, 1997
36. Parry D, Mahony D, Wills K, et al: Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19:1775-1783, 1999
37. Alt JR, Gladden AB, Diehl JA: p21(Cip1) promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277:8517-8523, 2002
38. Dulic V, Kaufmn W, Wilson S, et al: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994
39. Parker S, Eichele G, Zhang P, et al: p53-independent expression of p21Cip1 in muscle and other terminal differentiating cells. Science 267:1024-1027, 1995
40. Noda A, Ning Y, Venable SF, et al: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90-98, 1994
41. Polyak K, Lee M-H, Erdjument-Bromage H, et al: Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potent mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
42. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994
43. Brugarolas J, Chandrasekaran C, Gordon JI, et al: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557, 1995
44. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864, 1996
45. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 269:682-685, 1995
46. Coqueret O: New roles for p21 and p27 cell cycle inhibitors: A function for each cell compartment? Trends Cell Biol 13:65-70, 2003
47. Fahraeus R, Lane DP: The p16 (INK4a) tumour suppressor protein inhibits alpha v beta 3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localisation of alpha v beta 3 to focal contacts. EMBO J 18:2106-2118, 1999
48. Tanaka H, Yamashita T, Asada M, et al: Cytoplasmic p21(Cip1/WAF1) regulates neurite remodelling by inhibiting Rho-kinase activity. J Cell Biol 158:321-329, 2002
49. Lee M-H, Reynisdottir I, Massague J: Cloning of p57Kip2, a cyclin dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649, 1995
50. Matsuoka S, Edwards MC, Bai C, et al: p57Kip2, a structurally distinct member of the p21Cip1 CDK inhibitor family, is a candidate tumour suppressor gene. Genes Dev 9:650-662, 1995
51. Wolf G: Molecular mechanisms of renal hypertrophy: Role of p27Kip1. Kidney Int 56:1262-1265, 1999
52. Fero ML, Rivkin M, Tasch M, et al: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27kip1-deficient mice. Cell 85:733-744, 1996
53. Nakayama K, Ishida N, Shirane M, et al: Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumours. Cell 85:707-720, 1996
54. Zhang P, Liegeois NJ, Wong C, et al: Altered cell differentiation and proliferation in mice lacking p57Kip2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-158, 1997
55. Yan Y, Frisen J, Lee M-H, et al: Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 11:973-983, 1997
56. Takahashi K, Nakayama K-I, Nakayama K: Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem 127:73-83, 2000
57. Deng C, Zhang P, Harper JW, et al: Mice lacking p21Cip1/Waf1 undergo normal development but are defective in G1 checkpoint control. Cell 82:675-684, 1995
58. Elledge SJ: Cell cycle checkpoints: Preventing an identity crisis. Science 274:1664-1672, 1996
59. Klahr S, Schreiner G, Ichikawa I: Progression in renal disease. N Engl J Med 318:1666, 1988
60. Johnson RJ: The glomerular response to injury: progression or resolution? Kidney Int 45:1769-1782, 1994
61. Pesce CM, Striker LJ, Peten E, et al: Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic for growth hormone. Lab Invest 65:601-605, 1991
62. Couser WG, Johnson RJ: Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 23:193-198, 1994
63. Floege J, Johnson RJ, Gordon KL, et al: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40:477-488, 1991
64. Brandt J, Pippin J, Schulze M, et al: Role of complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49:335-343, 1996
65. Floege J, Eng E, Young BA, et al: Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int 43:369-380, 1993
66. Johnson RJ, Raines EW, Floege J, et al: Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet derived growth factor. J Exp Med 175:1413-1416, 1993
67. Gesualdo L, Di Paolo S, Ranieri E, et al: Trapidil inhibits human mesangial cell proliferation: Effect on PDGF B-receptor binding and expression. Kidney Int 46:1002-1009, 1994
68. Tsuboi Y, Shankland SJ, Grande JP, et al: Suppression of mesangial proliferative glomerulonephritis development in rats by inhibition of cAMP phosphodiesterase isoenzymes types III and IV. J Clin Invest 98:262-270, 1996
69. Yamamoto T, Wilson CB: Complement dependence of antibody-induced mesangial cell injury in the rat. J Immunol 138:3758-3765, 1987
70. Yamamoto T, Wilson CB: Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int 32:514-525, 1987
71. Shankland SJ, Hugo C, Coats SR, et al: Changes in cell-cycle protein expression during experimental mesangial proliferative nephritis. Kidney Int 50:1230-1239, 1996
72. Shankland SJ, Hamel P, Scholey JW: Cyclin and cyclin-dependent kinase expression in the remnant glomerulus. J Am Soc Nephrol 8:368-375, 1997
73. Schoecklmann HO, Rupprecht HD, Zauner I, et al: TGF-beta1 induced cell cycle arrest in renal mesangial cells involves inhibition of cyclin E-CDK2 activation and retinoblastoma protein phosphorylation. Kidney Int 51:1228-1236, 1996
74. Caspary T, Cleary MA, Perlman EJ, et al: Oppositely imprinted genes p57Kip2 and Igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev 13:3115-3124, 1999
75. Pippin J, Qu Q, Meijer L, et al: Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with roscovitine, a novel cyclin-dependent kinase antagonist. J Clin Invest 100:2512-2520, 1997
76. Shankland SJ, Pippin J, Flanagan M, et al: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27kip1. Kidney Int 51:1088-1099, 1997
77. Hiromura K, Haseley LA, Zhang P, et al: Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 60:2235-2246, 2001
78. Hiromura K, Pippin J, Fero ML, et al: Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27kip1. J Clin Invest 103:597-604, 1999
79. Ophascharoensuk V, Fero ML, Hughes J, et al: The cyclin-dependent kinase inhibitor p27kip1 safeguards against inflammatory injury. Nat Med 4:575-580, 1998
80. Baker AJ, Mooney A, Lombardi D, et al: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 94:2105-2116, 1994
81. Savill J: Regulation of glomerular cell number by apoptosis. Kidney Int 56:1216-1222, 1999
82. Hiromura K, Pippin J, Blonski MJ, et al: The subcellular localisation of cyclin dependent kinase 2 determines the fate of mesangial cells: Role in apoptosis and proliferation. Oncogene, 21:1750-1758, 2002
83. USRDS: U.S. Renal Data System, USRDS 2001 Annual Data Report: Atlas of end stage renal diseases in the US. Bethesda, MD, NIH, National Institution of Diabetes and Digestive and Kidney Disease, 2003
84. Ritz E, Keller C, Bergis K, et al: Pathogenesis and course of renal disease in IDDM/NIDDM: Differences and similarities. Am J Hypertens 10:202S-207S, 1997
85. McGowan TA, McCue P, Sharma K: Diabetic nephropathy. Clin Lab Med 21:111-146, 2001
86. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342-348, 1997
87. Cusumano AM, Bodkin NL, Hansen BC, et al: Glomerular hypertrophy is associated with hyperinsulinaemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis 40:1075-1085, 2002
88. Young BA, Johnson RJ, Alpers CE, et al: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47:935-944, 1995
89. Feliers D, Frank MA, Riley DJ: Activation of cyclin D1-CDK4 and CDK4-directed phosphorylation of RB protein in diabetic mesangial hypertrophy. Diabetes 51:3290-3299, 2002
90. waf1,Cip1 is increased in experimental diabetic nephropathy: Potential role in glomerular hypertrophy. J Am Soc Nephrol 9:986-993, 1998
91. Wolf G, Schroeder R, Ziyadeh FN, et al: High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells. Am J Physiol 42:F348-F356, 1997
92. Wolf G, Sharma K, Chen Y, et al: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF beta. Kidney Int 42:647-656, 1992
93. Ziyadeh FN, Sharma K, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor beta. J Clin Invest 93:536-542, 1994
94. Abdel Wahab N, Weston BS, Roberts T, et al: Connective tissue growth factor and regulation of the mesangial cell cycle: Role in cellular hypertrophy. J Am Soc Nephrol 13:2437-2445, 2002
95. Wolf G, Schroeder R, Thaiss F, et al: Glomerular expression of p27Kip1 in diabetic db/db mouse: Role of hyperglycaemia. Kidney Int 53:869-879, 1998
96. Wolf G, Hannken T, Zahner G, et al: p44/p42 MAP kinase directly phosphorylates the CDK inhibitor p27Kip1: Role in hypertrophy. J Am Soc Nephrol 12:623A(abstr), 2001
97. Wolf G, Schroeder R, Zahner G, et al: High glucose-induced hypertrophy of mesangial cells requires p27Kip1, an inhibitor of cyclin dependent kinases. Am J Pathol 158:1091-1100, 2001
98. Wolf G, Wengel U, Ziyadeh FN, et al: Angiotensin converting enzyme inhibitor treatment reduces glomerular p161NK4a and p27Kip1 expression in diabetic BBdp rats. Diabetologica 42:1425-1432, 1999
99. Hoshi S, Shu Y, Yoshida F, et al: Podocyte injury promotes progressive nephropathy in Zucker diabetic fatty rats. Lab Invest 82:25-35, 2002
100. Al-Douahji M, Brugarolas J, Brown PAJ, et al: The cyclin kinase inhibitor p21Waf1/Cip1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56:1691-1699, 1999
101. Megyesi J, Price P, Tamayo E, et al: The lack of a functional p21Waf1/Cip1 gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci U S A 96:10830-10835, 1999
102. Awazu M, Omori S, Ishikura K, et al: The lack of cyclin kinase p27Kip1 ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 14:699-708, 2003
103. Roberts AB, McCune BK, Sporn MB: TGF beta: Regulation of extracellular matrix. Kidney Int 41:557-559, 1992
104. Shankland SJ, Johnson RJ: TGF beta in glomerular disease. Miner Electrolyte Metab 24:168-173, 1998
105. Kopp JB, Factor VM, Mozes M, et al: Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74:991-1003, 1996
106. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393-405, 1999
107. Mackay K, Striker LJ, Stauffer JW, et al: Transforming growth factor beta. Murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest 83:1160-1167, 1989
108. Monkawa T, Hiromura K, Wolf G, et al: The hypertrophic effect of TGF beta is reduced in the absence of the cyclin dependent kinase inhibitors p21 and p27. J Am Soc Nephrol 13:1172-1178, 2002
109. Pavenstadt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 83:253-307, 2003
110. Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 13:3005-3015, 2002
111. Fries JW, Sandstrom DJ, Meyer TW, et al: Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest 60:205-218, 1989
112. Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 54:687-697, 1998
113. Nagata M, Nakayama K, Terada Y, et al: Cell cycle regulation and differentiation in the human podocyte lineage. Am J Kidney Dis 153:1511-1520, 1998
114. Tomari S, Nagahama H, Shu Y, et al: Glomerular differentiation in p27 and p57 double-mutant metanephroi. Anat Embryol 206:31-36, 2002
115. Salant DJ, Darby C, Couser WG: Experimental membranous glomerulonephritis in rats. J Clin Invest 66:71-81, 1980
116. Cybulsky AV, Remake HG, Feintzeig ID, et al: Complement-induced glomerular epithelial cell injury: Role of membrane attack complex in rat membranous nephropathy. J Clin Invest 77:1096-1107, 1986
117. Shankland SJ, Floege J, Thomas SE, et al: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial proliferation in vivo. Kidney Int 52:404-413, 1997
118. Kim Y-G, Alpers CE, Brugarolas J, et al: The cyclin kinase inhibitor p21Cip1/Waf1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 55:2349-2361, 1999
119. Durvasula RV, Pippin J, Petermann AT, et al: Sublytic C5b-9 induces DNA damage in podocytes in vitro: A novel response to injury which prevents proliferation. J Am Soc Nephrol 12:609A, 2001 (abstr)
120. Pippin J, Durvasula R, Petermann AT, et al: DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 111:877-885, 2003
121. Shankland SJ, Eitner F, Hudkins KL, et al: Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: Role in podocyte proliferation and maturation. Kidney Int 58:674-683, 2000
122. Barisoni L, Mokrzycki M, Sablay L, et al: Podocyte cell cycle regulation and proliferation in collapsing glomerulone-phropathies. Kidney Int 58:137-143, 2000
123. Nelson PJ, Gelman IH, Klotman PE: Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes. J Am Soc Nephrol 12:2827-2831, 2001
124. Nelson PJ, Sunamoto M, Husain M, et al: HIV-1 expression induces cyclin D1 expression and pRb phosphorylation in infected podocytes: Cell-cycle mechanisms contributing to the proliferative phenotype in HIV-associated nephropathy. BMC Microbiol 2:26, 2002
125. Brenner BM: Nephron adaptation to renal injury or ablation. Am J Physiol 249:F324-F337, 1985
126. Weir MR: Diabetes and hypertension: Blood pressure control and consequences. Am J Hypertens 12:170S-178S, 1999
127. Harris RC, Haralson MA, Badr KF: Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Biochem J 313:697-710, 1992
128. Petermann AT, Hiromura K, Blonski MJ, et al: Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 61:40-50, 2002
129. Kang D-H, Kanellis J, Hugo C, et al: Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13:806-816, 2002
130. Kim Y-G, Suga S-I, Kang D-H, et al: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58:2390-2399, 2000
131. Masuda Y, Shimizu A, Mori T, et al: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159:599-608, 2001
132. Kang D-H, Hughes J, Mazzali M, et al: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilises renal function. J Am Soc Nephrol 12:1448-1457, 2001
133. Shankland SJ, Wolf G: Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation and apoptosis. Am J Physiol 278:F515-F529, 2000
134. Shankland SJ, Scholey JW: Expression of transforming growth factor beta 1 during diabetic renal hypertrophy. Kidney Int 47:430-442, 1994